ALDEYRA THERAPEUTICS, INC. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- ALDEYRA THERAPEUTICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $0.00.
- ALDEYRA THERAPEUTICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $71.14K, a 92.76% decline year-over-year.
- ALDEYRA THERAPEUTICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2025-12-31 was $0.00.
- ALDEYRA THERAPEUTICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $120.75K.
- ALDEYRA THERAPEUTICS, INC. stock issued during period, value, stock options exercised for fiscal 2025 was $1.10M, a 215.16% increase from fiscal 2024.
- ALDEYRA THERAPEUTICS, INC. stock issued during period, value, stock options exercised for fiscal 2024 was $350.28K, a 80.44% increase from fiscal 2023.
- ALDEYRA THERAPEUTICS, INC. stock issued during period, value, stock options exercised for fiscal 2023 was $194.13K, a 82.72% decline from fiscal 2022.
- ALDEYRA THERAPEUTICS, INC. stock issued during period, value, stock options exercised for fiscal 2022 was $1.12M, a 75.70% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $191.89K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $71.14K 10-Q · filed 2026-05-07 | $191.89K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $1.10M 10-K · filed 2026-02-27 |
| 2025-09-30 | $120.75K 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | |
| 2025-03-31 | $983.19K 10-Q · filed 2026-05-07 | |
| 2024-12-31 | $350.28K 10-K · filed 2026-02-27 | |
| 2023-12-31 | $30.19K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $194.13K 10-K · filed 2025-02-28 |
| 2023-09-30 | $158.65K 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $5.29K 10-Q · filed 2024-08-01 | |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | $1.12M 10-K · filed 2024-03-07 |
| 2022-09-30 | $1.12M 10-Q · filed 2023-11-03 | |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-04 | $658.49K derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $4.62M 10-K · filed 2023-03-09 |
| 2021-09-30 | $51.65K 10-Q · filed 2022-11-10 | $4.66M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $606.84K 10-Q · filed 2022-08-05 | $5.61M derived: sum of 4 quarters · filed 2022-08-05 |
| 2021-03-31 | $4.00M 10-Q · filed 2022-05-05 | $5.05M derived: sum of 4 quarters · filed 2022-05-05 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $1.06M 10-K · filed 2022-03-17 |
| 2020-09-30 | $998.10K 10-Q · filed 2021-10-28 | |
| 2020-06-30 | $50.15K 10-Q · filed 2021-08-05 | |
| 2020-03-31 | $10.27K 10-Q · filed 2021-05-06 | |
| 2019-12-31 | $1.16M 10-K · filed 2021-03-11 | |
| 2016-12-31 | $89.08K 10-K · filed 2018-03-29 | |
| 2008-12-31 | $6.50K 10-Q · filed 2014-06-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |